The Gynecologic Cancer market was impacted by ovarian, cervical and endometrial data presented during the Society of Gynecologic Oncology (SGO) meeting in Honolulu, Hawaii.

Breaking Data worked with 30 oncologists during the meeting to better understand the commercial implications of data presented for TECENTRIQ® (atezolizumab), AVASTIN® (bevacizumab), NERLYNX® (neratinib), ZEJULA® (niraparib), KEYTRUDA® (pembrolizumab), LYNPARZA® (olaparib), RUBRACA® (rucaparib), dostarlimab and tisotumab vedotin.

Companies presenting data included: AstraZeneca, Clovis, Genentech, Merck, Puma, Seattle Genetics, Tesaro/GSK.

Get immediate access to this 59-slide report so you can make better decisions today and prepare for tomorrow.

Gynecologic Cancer SGO 2019

Honolulu, Hawaii
Mar 16 to Mar 19


SOLO1 (olaparib) data are practice-changing for newly diagnosed advanced ovarian cancer patients. Oncologists were bullish, stating, “this is a landmark study that will change the standard of care.” Based on these data, olaparib is expected to become the first PARP inhibitor to be used as maintenance for newly diagnosed women with BRCA-mutated advanced ovarian cancer. In the advanced ovarian cancer second-line maintenance setting, data for niraparib and rucaparib reinforce current usage.

With regard to cervical cancer, the efficacy of neratinib in patients with HER2+ metastatic cervical cancer (mCC) and tisotumab vedotin in heavily pre-treated mCC (all comers) are of significant interest in light of a dearth of effective options. With regard to neratinib, oncologists note that, “metastatic cervical patients are hard to treat; even though the HER2 mutation is a small subgroup, there was a response rate in those patients; it’s worth pursing further.”

Dostarlimab in patients with recurrent or advanced endometrial cancer is appealing in light of demonstrated efficacy in both MSI-H and MSS patients (patients in the latter cohort have very few treatment options). Oncologists noted that, “Dostarlimab is a novel PD-1 treatment demonstrating activity and durability in relapsed/refractory endometrial cancer … in a targeted group of patients.”

Get the Report

Stay Connected with Hem/Oncs at ASH 2020

Learn More